1. Home
  2. RMTI vs MURA Comparison

RMTI vs MURA Comparison

Compare RMTI & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rockwell Medical Inc.

RMTI

Rockwell Medical Inc.

HOLD

Current Price

$0.92

Market Cap

35.1M

Sector

Health Care

ML Signal

HOLD

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.03

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMTI
MURA
Founded
1994
2013
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.1M
36.0M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
RMTI
MURA
Price
$0.92
$2.03
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$2.50
$6.00
AVG Volume (30 Days)
226.0K
224.8K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,577,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$0.95
52 Week High
$2.41
$4.74

Technical Indicators

Market Signals
Indicator
RMTI
MURA
Relative Strength Index (RSI) 43.56 40.39
Support Level $0.87 $2.06
Resistance Level $0.97 $2.10
Average True Range (ATR) 0.06 0.01
MACD 0.01 -0.01
Stochastic Oscillator 34.62 25.00

Price Performance

Historical Comparison
RMTI
MURA

About RMTI Rockwell Medical Inc.

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: